-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Orthopoxvirus
- Others
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Virus Protease
- Antiviral intermediates
AN-12-H5
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/1193340-31-6.gif)
| Category | Enterovirus (EV) |
| CAS | 1193340-31-6 |
| Description | AN-12-H5, an antienterovirus compound, targets the replication processes of PV and enterovirus 71 (EV71). AN-12-H5 is a bifunctional, enviroxime-like anti-Enterovirus compound that inhibits replication and the early stage of enterovirus 71 infection with EC50 of 0.55 uM; mutations in capsid proteins (G3112A, VP1-Ala224Thr, and G2396A, VP3-Arg227Lys mutations) are resistant to AN-12-H5. |
Product Information
| Synonyms | AN-12-H5|1193340-31-6|N-((6AS,8S)-2-(4-(methylthio)phenyl)-6,12-dioxo-5,6,6a,7,8,9,10,12-octahydrobenzo[e]pyrido[1,2-a][1,4]diazepin-8-yl)thiophene-2-sulfonamide|ACon0_001263|HY-120900 |
| Molecular Weight | 513.645 |
| Molecular Formula | C24H23N3O4S3 |
| Canonical SMILES | CSC1=CC=C(C=C1)C2=CC3=C(C=C2)NC(=O)C4CC(CCN4C3=O)NS(=O)(=O)C5=CC=CS5 |
| Purity | >99.50% |
| Solubility | DMSO: 100 mg/mL (54.08 mM); H2O: < 0.1 mg/mL (insoluble) |
| Appearance | Solid powder |
| Storage | Powder: -20°C: 3 years 4°C: 2 years In solvent: -80°C: 6 months -20°C: 1 month |
| Complexity | 871 |
| Exact Mass | 513.08506974 |
| In Vitro | AN-12-H5 shows no inhibitory effect on PI4KB activity and only moderate inhibitory effects on PI 3-kinase activity. |
| In Vivo | AN-12-H5 shows no inhibitory effect on PI4KB activity and only moderate inhibitory effects on PI 3-kinase activity. |
| Target | Enterovirus |
| XLogP3-AA | 3.8 |
